



**Professor Yae-Jean Kim, MD, PhD, FIDSA**

**Biography**

Yae-Jean Kim is a Professor in the Division of Infectious Diseases and Immunology, Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea.

She received her MD degree from Ewha Womans University and completed her training in Pediatrics and Pediatric Infectious Diseases in Korea. She subsequently pursued immunology research at the U.S. National Institutes of Health and received further training in infections in immunocompromised hosts at Seattle Children's Hospital and Fred Hutchinson Cancer Center. After returning to Korea in 2008, she pioneered clinical care and research in infections in immunocompromised hosts and inborn errors of immunity (IEI). In 2017, she established Korea's first prospective national IEI registry and subsequently expanded this initiative through the Korean Immunodeficiency Network (KINET).

Dr. Kim was one of the founding members of the Asia Pacific Society for Immunodeficiencies (APSID) in 2015 and has served as a member of its Executive Board. She has contributed to strengthening the APSID IEI Registry by helping update its electronic case report forms and facilitating the drafting of standardized Institutional Review Board documents for participating centers. She has remained actively involved in APSID activities and currently serves as Chair of the Clinical Care Working Party. She will also host the next APSID Congress in Seoul in 2027.

**Dr. Kim's Vision for APSID**

Over the past decade, APSID has grown into a community of dedicated clinicians and researchers who share a common commitment to improving the lives of patients with IEI. Across the Asia-Pacific region, our members are making contributions, both individually and collaboratively, despite the wide diversity in healthcare resources and clinical settings.

Many patients with IEI in our region still face significant barriers to timely diagnosis and access to treatment, including established therapies such as immunoglobulin replacement and hematopoietic stem cell transplantation, as well as newer targeted therapies. Nevertheless, our members continue to work tirelessly, each in their own setting and capacity, to provide better care for our patients while advancing our understanding of the human immune system.

Since its establishment, APSID has played an important role in inspiring and nurturing the next generation of clinicians and researchers through educational initiatives such as the IEI School and training opportunities at Centers of Excellence. I believe that these efforts will continue to cultivate future leaders in our region. At the same time, strengthening the APSID IEI Registry and expanding collaborative research will enable us to keep generating valuable regional data and translate our collective experience into better patient care.

With rapid advances in genetic diagnosis and the growing recognition of rare diseases, awareness of IEI is increasing across many countries. The emergence of novel targeted therapies also offers unprecedented opportunities to improve the diagnosis and treatment of patients with IEI. However, ensuring that these advances reach patients across our diverse region remains an important challenge.

I envision APSID as a society that brings people together across borders and resource settings, supports the next generation of leaders, and transforms our collective knowledge and experience into meaningful improvements in patient care. Through our collaborative efforts, I hope we can further raise awareness of IEI among healthcare professionals, the general public, and policymakers, while advocating for better access to diagnosis and treatment.

Having been part of APSID since its beginning, I have witnessed firsthand the dedication, enthusiasm, and friendship that have shaped our society. I believe these are our greatest strengths. I am confident that APSID will continue to play a vital role in advancing the field of IEI throughout the Asia-Pacific region, and I would be honored to participate in its continued growth and future success.